GDRXNasdaqServices-Computer Processing & Data PreparationFiscal year ends December 31
GoodRx Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.37+0.01 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- 84.3
- Dividend yield
- –
GoodRx statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Computer Processing & Data Preparation companies for comparison
Valuation
| Measure | GoodRx | Industry median |
|---|---|---|
| Market Cap | $1.15B | $283.76M |
| Enterprise Value | $1.34B | $296.20M |
| PE Ratio | 84.25 | 25.42 |
| PS Ratio | 1.46 | 2.36 |
| PB Ratio | 1.78 | 2.67 |
| P/TBV Ratio | 7.23 | 4.90 |
| P/FCF Ratio | 5.83 | 15.01 |
| P/OCF Ratio | 5.70 | 13.05 |
Enterprise value
| Measure | GoodRx | Industry median |
|---|---|---|
| EV / Sales | 1.71 | 2.14 |
| EV / EBITDA | 8.19 | 16.16 |
| EV / EBIT | 17.88 | 21.55 |
| EV / FCF | 6.80 | 15.07 |
Income (trailing twelve months)
| Measure | GoodRx | Industry median |
|---|---|---|
| Revenue | $785.23M | $289.17M |
| Gross Profit | $713.19M | $161.98M |
| Operating Income | $74.94M | -$613.24K |
| Pretax Income | $41.40M | -$294.07K |
| Net Income | $16.25M | -$301.07K |
| EBITDA | $163.58M | -$156.35K |
| EPS (Diluted) | $0.04 | $0.00 |
Margins
| Measure | GoodRx | Industry median |
|---|---|---|
| Gross Margin | 90.8% | 55.8% |
| Operating Margin | 9.54% | -1.81% |
| Pretax Margin | 5.27% | -0.50% |
| Profit Margin | 2.07% | -1.80% |
| EBITDA Margin | 20.8% | 0.60% |
| FCF Margin | 25.1% | 10.0% |
Returns
| Measure | GoodRx | Industry median |
|---|---|---|
| Return on Equity (ROE) | 2.52% | 0.83% |
| Return on Assets (ROA) | 0.89% | -2.82% |
| Return on Invested Capital (ROIC) | 4.44% | -0.05% |
| Return on Capital Employed (ROCE) | 6.32% | -0.44% |
Growth
| Measure | GoodRx | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -1.83% | 9.72% |
| Net Income Growth (YoY) | -53.0% | 7.14% |
| EPS Growth (YoY) | -60.0% | 8.91% |
| FCF Growth (YoY) | 4.01% | 17.2% |
| Revenue Growth (3Y CAGR) | 1.30% | 7.66% |
| Revenue Growth (5Y CAGR) | 7.67% | 12.4% |
Balance sheet
| Measure | GoodRx | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $296.11M | $43.42M |
| Total Debt | $486.59M | $204.00M |
| Net Cash (Debt) | -$190.48M | $2.04M |
| Net Cash Per Share | -$0.56 | $0.15 |
| Equity (Book Value) | $647.60M | $52.29M |
| Book Value Per Share | $1.90 | $1.93 |
| Tangible Book Value | $159.02M | $3.06M |
| Working Capital | $441.46M | $15.22M |
Financial position
| Measure | GoodRx | Industry median |
|---|---|---|
| Current Ratio | 1.38 | 1.40 |
| Quick Ratio | 0.41 | 0.94 |
| Debt / Equity | 0.75 | 0.53 |
| Debt / EBITDA | 2.97 | 2.78 |
| Debt / FCF | 2.47 | 2.83 |
| Net Debt / EBITDA | 1.16 | 1.50 |
| Interest Coverage | 1.84 | -0.66 |
Cash flow (trailing twelve months)
| Measure | GoodRx | Industry median |
|---|---|---|
| Operating Cash Flow | $201.58M | $8.52M |
| Capital Expenditures | -$4.49M | -$5.56M |
| Free Cash Flow | $197.09M | $43.71M |
| FCF Per Share | $0.58 | $0.69 |
Efficiency
| Measure | GoodRx | Industry median |
|---|---|---|
| Asset Turnover | 0.43 | 0.64 |
| Revenue Per Employee | $1.13M | $392.99K |
| Profits Per Employee | $23.31K | -$4.47K |
| Employee Count | 697 | 531 |
Dividends and yields
| Measure | GoodRx | Industry median |
|---|---|---|
| Earnings Yield | 1.41% | -0.92% |
| FCF Yield | 17.1% | 4.02% |
| Buyback Yield | 7.39% | 3.11% |
| Shareholder Yield | 7.39% | 3.32% |
Shares
| Measure | GoodRx | Industry median |
|---|---|---|
| Shares Outstanding | 341,145,000 | 58,826,100 |
| Shares Change (YoY) | -8.76% | 2.21% |
| Float | 185,681,000 | 52,938,050 |
| Shares Held by Insiders | 45.6% | 13.2% |
| Shares Held by Institutions | 34.8% | 66.9% |
Taxes
| Measure | GoodRx | Industry median |
|---|---|---|
| Income Tax | $25.15M | $1.69M |
| Effective Tax Rate | 60.7% | 22.0% |
Scores
| Measure | GoodRx | Industry median |
|---|---|---|
| Graham Number | $1.31 | $15.96 |
| Graham Upside | -61.2% | -55.7% |
| Altman Z-Score | 0.24 | 1.50 |
| Piotroski F-Score | 7 | 5 |
| Beneish M-Score | -2.40 | -2.80 |
Calculated by StockData from GoodRx's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.